- Home
- CISO vs CVKD Comparison
CISO vs CVKD Comparison
Compare CISO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- CVKD
- Stock Information
- Founded
- CISO 2015
- CVKD 2022
- Country
- CISO United States
- CVKD United States
- Employees
- CISO N/A
- CVKD N/A
- Industry
- CISO Computer Software: Prepackaged Software
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- CISO Technology
- CVKD Health Care
- Exchange
- CISO Nasdaq
- CVKD Nasdaq
- Market Cap
- CISO 31.4M
- CVKD 29.5M
- IPO Year
- CISO N/A
- CVKD 2023
- Fundamental
- Price
- CISO $1.08
- CVKD $11.37
- Analyst Decision
- CISO
- CVKD Strong Buy
- Analyst Count
- CISO 0
- CVKD 1
- Target Price
- CISO N/A
- CVKD $32.00
- AVG Volume (30 Days)
- CISO 963.0K
- CVKD 36.4K
- Earning Date
- CISO 08-13-2025
- CVKD 08-06-2025
- Dividend Yield
- CISO N/A
- CVKD N/A
- EPS Growth
- CISO N/A
- CVKD N/A
- EPS
- CISO N/A
- CVKD N/A
- Revenue
- CISO $29,887,603.00
- CVKD N/A
- Revenue This Year
- CISO N/A
- CVKD N/A
- Revenue Next Year
- CISO N/A
- CVKD N/A
- P/E Ratio
- CISO N/A
- CVKD N/A
- Revenue Growth
- CISO N/A
- CVKD N/A
- 52 Week Low
- CISO $0.26
- CVKD $5.70
- 52 Week High
- CISO $3.84
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- CISO 47.60
- CVKD 39.88
- Support Level
- CISO $0.97
- CVKD $11.15
- Resistance Level
- CISO $1.19
- CVKD $12.26
- Average True Range (ATR)
- CISO 0.08
- CVKD 1.07
- MACD
- CISO -0.01
- CVKD 0.01
- Stochastic Oscillator
- CISO 38.41
- CVKD 13.68
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.